NCT02269540View on ClinicalTrials.gov

A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A)

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

June 30, 2018

Study Completion Date

July 31, 2018

Conditions
Major Depressive Disorder
Interventions
DRUG

Sertraline

selective serotonin reuptake inhibitor

DRUG

Citalopram

selective serotonin reuptake inhibitor

DRUG

N-acetylcysteine (NAC)

natural health product

DRUG

Existing depression medication treatment

Continuation of depression medication treatment already taken prior to study enrollment except for drugs with affinity for MAO-A or potentially influencing MAO-A levels, including phenelzine, tranylcypromine, moclobemide, cytomel and lithium

Trial Locations (1)

M5T 1R8

Research Imaging Centre, Centre for Addiction and Mental Health, Toronto

All Listed Sponsors
lead

Centre for Addiction and Mental Health

OTHER

NCT02269540 - A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A) | Biotech Hunter | Biotech Hunter